10x Genomics, Inc.
For the period ended Mar 31, 2026. Filed May 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 8, 2026
TXG$62.90-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities: | ||
| Net loss | $(13,470) | $(34,358) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Stock-based compensation expense | 22,642 | 31,076 |
| Depreciation and amortization | 9,957 | 8,022 |
| Non-cash lease expense | 1,953 | 1,792 |
| Fair value adjustments on contingent consideration | (57) | — |
| Asset and lease impairment charges | — | 114 |
| Other | (193) | (575) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 7,980 | 35,325 |
| Other receivables | 18,129 | — |
| Inventory | 2,702 | 8,058 |
| Prepaid expenses and other current assets | 1,945 | (5,530) |
| Other noncurrent assets | 282 | 2,314 |
| Accounts payable | 4,782 | (2,547) |
| Accrued compensation and other related benefits | (20,956) | (11,745) |
| Deferred revenue | 77 | 347 |
| Accrued contingent consideration and assumed liabilities | (613) | — |
| Accrued expenses and other current liabilities | (6,136) | 4,329 |
| Operating lease liability | (2,854) | (2,631) |
| Other noncurrent liabilities | (50) | 360 |
| Net cash provided by operating activities | 26,120 | 34,351 |
| Investing activities: | ||
| Purchases of property and equipment | (1,597) | (1,893) |
| Purchases of marketable securities | (24,714) | — |
| Proceeds from maturities of marketable securities | 25,000 | — |
| Net cash used in investing activities | (1,311) | (1,893) |
| Financing activities: | ||
| Issuance of common stock from exercise of stock options | 273 | 422 |
| Payment of contingent consideration | (8,690) | — |
| Net cash provided by (used in) financing activities | (8,417) | 422 |
| Effect of exchange rates changes on cash and cash equivalents | (73) | 114 |
| Net increase in cash and cash equivalents | 16,319 | 32,994 |
| Cash and cash equivalents at beginning of period | 473,966 | 344,067 |
| Cash and cash equivalents at end of period | $490,285 | $377,061 |
| Supplemental disclosures of cash flow information: | ||
| Net cash paid for (received from) income taxes | $(278) | $462 |
| Noncash investing and financing activities: | ||
| Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities | $118 | $398 |
| Issuance of Class A common stock for settlement of contingent consideration | $8,703 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.